Human Monoclonal Antibodies to HIV-1 Envelope Glycoprotein gp120
Description of Invention:
The human immunodeficiency virus (HIV) is the causative agent of acquired immunodeficiency syndrome (AIDS). Drug-resistance is a critical factor contributing to the gradual loss of clinical benefit to treatments for HIV infection. Accordingly, combination therapies have further evolved to address the mutating resistance of HIV. However, there has been great concern regarding the apparent growing resistance of HIV strains to current therapies.
The present invention relates to human monoclonal antibodies to type 1 human immunodeficiency virus (HIV-1) envelope glycoprotein gp120, to phage display libraries, and to diagnostic methods and pharmaceutical compositions which employ these antibodies therapeutically and prophylactically.
Inventors:
Brynmor A. Watkins and Marvin S. Reitz Jr. (NCI)
Patent Status:
DHHS Reference No. E-135-1998/0 Licensing Status: This technology is no longer available for licensing.
For Additional Information Please Contact: Sally Hu PhD MBA
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301) 435-5606
Email: hus@mail.nih.gov
Fax: (301) 402-0220
